Charles River Laboratories Intl. Inc vs Herbalife Nutrition Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Herbalife Nutrition Ltd trades at $12.54 (market cap $1.27B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.8× Herbalife Nutrition Ltd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| CRL | HLF | |
|---|---|---|
Market Cap | $11.14B | $1.27B |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $19.96 |
52-Week Low | $145.57 | $7.75 |
Enterprise Value | $14.00B | $3.00B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Herbalife (HLF) trades at $13.10, down 0.38% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 77.78% gross margin and attractive valuation metrics including a P/E of 5.75 and P/S of 0.27. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, while the company completed a $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.
The outlook remains positive with analyst consensus favoring Buy ratings (57.69%) and improving debt-to-asset ratios from 82.84% in 2024 to 71.67% in 2025. Key risks include high leverage, competitive pressures in the nutrition space, and regional market volatility. The stock offers value appeal given low multiples and recent strategic initiatives to expand digital health offerings.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →